Immune Thrombocytopenia Market Insights, Epidemiology, and Market Forecast - 2032

DelveInsight's "Immune Thrombocytopenic Purpura (ITP) - Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of ITP historical and forecasted epidemiology as well as the ITP market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

The ITP market report provides current treatment practices, emerging drugs, and market share of individual therapies, current and forecasted 7MM ITP market size. The report also covers a descriptive overview of ITP, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, Spain) and the UK
• Japan

Study Period: 2019-2032.

ITP Understanding

ITP Overview

ITP, previously called immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder that occurs when the body attacks its platelets and destroys them quickly. ITP is a disorder that affects the overall number of blood platelets rather than their function. The normal platelet level in adults is between 150,000/mm3 and 450,000/mm3. Platelet counts below 50,000/mm3 increase the risk of dangerous bleeding from trauma; counts below 20,000/mm3 increase the risk of spontaneous bleeding.

Classification of ITP

ITP is caused by various etiologies characterized by increased platelet destruction and impaired production, resulting in a decreased platelet count. Primary ITP is idiopathic, whereas secondary ITP is linked to an underlying condition. When PNH is associated with AA, most patients express only a small PNH clone (<10%). Physicians could find clinical and/or biological evidence of hemolysis associated with two or three cytopenias (Hb <10 g/dL, neutrophils <1,000/μL, platelets <80,000/μL). In general, bone marrow failure dominates the clinical picture.

ITP can also be classified by disease duration. ITP has been categorized into new-onset (acute) for those diagnosed within the last 3 months, persistent for those between 3 months and 12 months, and chronic for those who have had the disease for more than 1 year. In acute ITP cases, patients usually suffer from bruising; petechia, nosebleeds, and bleeding gums may occur if the platelet count is below 20,000/mm3 compared with a normal range of 150,000-400,000/mm3. In extreme cases, patients with ITP may bleed into the lungs, brain, or other vital organs, leading to subarachnoid, intracerebral hemorrhage, or other internal bleeding are possible severe complications of this disease.

Continued in the report…

ITP Epidemiology

The epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of ITP, Age-specific Diagnosed Prevalent Cases of ITP and Gender-specific Diagnosed Prevalent Cases of ITP scenario in the 7MM covering the United States, the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom and Japan from 2019 to 2032.

Key Findings

• In 2021, the total cases of ITP were ~184,000 cases in the 7MM. These cases are expected to increase by 2032.
• The United States, in 2021, accounted for the highest number of cases of ITP that were ~ 65,500 cases. These cases are expected to increase by the year 2032.
• In 2021, Japan accounted for ~27,200 cases of ITP, which was approximately 15% of the total ITP cases in 7MM.
• In the UK, out of the total diagnosed prevalent cases, there were ~570 cases and ~21,400 cases ITP in children and adults, respectively in 2021. These cases are expected to increase by 2032.
• Out of the total diagnosed prevalent cases, Japan accounted for ~740 cases in children and ~21,200 cases of ITP in adults in 2021.

ITP Drug Chapters

ITP Emerging Drugs

Rilzabrutinib: Sanofi

Rilzabrutinib (PRN-1008) is an orally administered reversible covalent inhibitor of Bruton tyrosine kinase (BTK). BTK is an essential signaling element downstream of the B-cell receptor (BCR), Fc-gamma receptor, and Fc-epsilon receptor pathways. BTK activation is critical for B-cell activation and maturation. BTK also regulates antibody-mediated activation of other immune cells, such as macrophages, neutrophils, and mast cells, through Fc receptor signaling.

Efgartigimod: Argenx

Efgartigimod (ARGX-113) is an investigational therapy for IgG-mediated autoimmune diseases and was designed to exploit the natural interaction between IgG antibodies and the recycling receptor FcRn Argenx, designed efgartigimod to degrade circulating disease-causing autoimmune antibodies and has potential in many large and orphan indications, namely multiple sclerosis, ITP, systemic lupus erythematosus, myasthenia gravis, and skin-blistering diseases.

Product details in the report…

ITP Market Outlook

ITP is characterized by low platelet counts and an increased tendency to bleed. Although ITP generally presents as a subtle-onset, chronic disorder in adults, clinical manifestations can range from petechia, purpura, and bruising to overt bleeding, such as gastrointestinal or intracranial hemorrhaging. When treatment is deemed necessary, typical first-line therapies include corticosteroids, intravenous immunoglobulin (IVIg), and Rho (D) immune globulin, also referred to as anti-D immune globulin (IV anti-D). Relapse or failure to respond to these drugs may necessitate second-line treatment, including various medical options and splenectomy.

In ITP, the first-line treatment option is generally corticosteroids. The recommended prednisone dose is 1 mg/kg/day orally for up to 21-28 days depending upon the response, followed by slow tapering. More prominent platelet responses have been reported with repeated pulses of high-dose dexamethasone 40 mg daily for 4 days.

Also, intravenous immunoglobulin or intravenous anti-D (Rho [D] immune globulin) is used as an initial treatment with or without steroids. Most adult patients will relapse after initial treatment (or are refractory to first-line therapy) and require second-line therapy. Intravenous immunoglobulin (IVIG) therapy is administered to patients requiring rapid or urgent elevation of platelet count (e.g., intraoperative or life-threatening bleeding). IVIg increases the platelet count in 70-80% of treated patients, often within days. Several IVIg regimens have been employed, but many hematologists prefer the convenience of a 1 g/kg/day infusion for 1-2 days. Anti-D immunoglobulin (anti-D) binds to Rh (D) antigen on erythrocytes, thereby leading to the clearance of antibody-coated cells and inhibiting the clearance of opsonized platelets by the reticuloendothelial system. Therefore, anti-D is effective only in RhD-positive individuals, and anti-D has been reported effective in approximately 50-70% of patients treated with this agent.

Continued in the report…..

Key Findings

• The market size of ITP in the 7MM was ~USD 3,100 million in 2021.
• In 2021, the US has the largest ITP market size of ~USD 1,860 million among the 7MM countries.
• Among the EU4 countries, Germany had the highest market size for ITP in 2021, i.e., ~USD 200 million. The lowest market size was estimated in Spain with ~USD 130 million in 2021.
• In Japan, the market size for ITP was ~USD 290 million in 2021.

The US Market Outlook

This section provides the total ITP market size and market size by therapies in the United States.

EU4 and the UK Market Outlook

The total ITP market size and market size by therapies in EU4 (Germany, France, Italy, Spain) and the United Kingdom are provided in this section.

Japan Market Outlook

The total ITP market size and market size by therapies in Japan are provided.

ITP Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the ITP market or expected to get launched in the market during the study period 2019-2032. The analysis covers the ITP market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, and reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

ITP Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions, merger, licensing, and patent details for ITP emerging therapies.

Reimbursement Scenario in ITP

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive market Intelligence analysis of the ITP market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers a descriptive overview of ITP, explaining its procedure, types, indications, and currently available therapies.
• Comprehensive insight has been provided into ITP epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for ITP is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the ITP market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM ITP market.

Report Highlights:

• The robust pipeline with novel MOA and oral ROA, increasing prevalence, and effectiveness of drugs will positively drive the ITP market.
• The companies and academics are working to assess challenges and seek opportunities that could influence ITP R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition using ITP.
• Major players are involved in developing therapies for ITP. The launch of emerging therapies will significantly impact the ITP market.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

ITP Report Insights

• Patient Population
• Therapeutic Approaches
• ITP Pipeline Analysis
• ITP Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

ITP Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• ITP Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

ITP Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• SWOT analysis

Key Questions

Market Insights:

• What was the ITP market share (%) distribution in 2019 and how it would look like in 2032?
• What would be the ITP total market size as well as market size by therapies across the 7MM during the forecast period (2022-2032)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest ITP market size during the forecast period (2022-2032)?
• At what CAGR, the ITP market is expected to grow at the 7MM level during the forecast period (2022-2032)?
• What would be the ITP market outlook across the 7MM during the forecast period (2022-2032)?
• What would be the ITP market growth till 2032 and what will be the resultant market size in the year 2032?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the risk, burdens, and unmet needs of ITP?
• What is the historical ITP patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the UK, and Japan?
• What would be the forecasted patient pool of ITP at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to ITP?
• Out of the above-mentioned countries, which country would have the highest cases of ITP during the forecast period (2022-2032)?
• At what CAGR are these cases expected to grow across the 7MM during the forecast period (2022-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current treatment practices in ITP along with the approved therapy?
• What are the current treatment guidelines for ITP?
• What are the ITP marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for ITP?
• How many emerging therapies are in the mid-stage and late stages of development for ITP?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the ITP therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for ITP and their status?
• What are the key designations that have been granted for the emerging therapies for ITP?
• What are the 7MM historical and forecasted market of ITP?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving ITP.
• To understand the future market competition in the ITP market and an insightful review of the market.
• Organize sales and marketing efforts by identifying the best opportunities for ITP in the US, Europe (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the ITP market.
• To understand the future market competition in the ITP market.